Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 815-822

  Kwun, J ^a   Page, E ^a   Hong, J J ^b,c   Gibby, A ^a   Yoon, J ^a   Farris, A B ^b   Villinger, F ^b,c   Knechtle, Stuart J ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

alloantibody; animal models: nonhuman primate; B cell biology; basic (laboratory) research science; immunosuppression immune modulation; kidney transplantation nephrology; rejection: antibody mediated (ABMR); translational research science

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; METHYLPREDNISOLONE; TACROLIMUS; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN; TNFSF13B PROTEIN, HUMAN;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY MEDIATED REJECTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; KIDNEY GRAFT; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; ANIMAL MODEL; ANTIBODY PRODUCTION; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; RHESUS MONKEY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; B-CELL ACTIVATING FACTOR; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MACACA MULATTA; MALE; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84924018287     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13045     Document Type: Article

References (29)

1. Terasaki PI, Cai J., Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
2. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331.
3. Wahrmann M, Exner M, Schillinger M, et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6 (5 Pt 1): 1033-1041.
4. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-2114.
5. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
6. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Annals of the New York Academy of Sciences 2005; 1050: 34-39.
7. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9: 1835-1845.
8. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ., B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010; 30: 99-105.
9. Mackay F, Schneider P., Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491-502.
10. Stohl W., Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 2014; 18: 473-489.
11. Gatto B., Atacicept a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 2008; 9: 1216-1227.
12. Page EK, Page AJ, Kwun J, et al. Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant 2012; 12: 2395-2405.
13. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014; 14: 59-69.
14. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746-749.
15. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
16. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
17. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
18. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662-1672.
19. Gloor J, Cosio F, Lager DJ, Stegall MD., The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373.
20. Colvin RB., CADI, Canti, Cavi. Transplantation 2007; 83: 677-678.
21. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
22. Cosio FG, Lager DJ, Lorenz EC, Amer H, Gloor JM, Stegall MD., Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010; 89: 1088-1094.
23. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681-685.
24. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280.
25. Smith RN, Malik F, Goes N, et al. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 2012; 27: 107-113.
26. Zarkhin V, Li L, Sarwal MM., BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 2009; 88: 1229-1230.
27. Banham G, Prezzi D, Harford S, et al. Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation 2013; 96: 413-420.
28. MacLennan IC, Toellner KM, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev 2003; 194: 8-18.
29. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180: 3655-3659.